Navigation Links
Neogen's Rapid Test for Salmonella enteritidis Receives FDA Approval
Date:1/12/2011

LANSING, Mich., Jan. 12, 2011 /PRNewswire/ -- Neogen Corporation (Nasdaq: NEOG) today announced that its rapid test for Salmonella enteritidis (SE) has been determined by the U.S. Food and Drug Administration (FDA) to be equivalent to the FDA's traditional testing method in accuracy, precision, and sensitivity for detecting SE.

The FDA's determination of equivalency will allow egg producers and processors to use Neogen's Reveal for SE to shorten the testing time and comply with the FDA's recently implemented SE-regulations without further scrutiny. In November, the AOAC International validated the accuracy of the Reveal for SE system when testing either environmental or egg samples.

"The FDA's determination of equivalency further validates our test as an invaluable tool to egg producers, as they comply with the FDA's new regulations, and seek to further reduce the likelihood of SE-contaminated eggs reaching consumers," said Ed Bradley, Neogen's vice president of Food Safety. "Until our introduction of an effective rapid test for SE, the industry had to wait up to 7 days for an outside laboratory's test results. Reveal for SE enables the industry to get quicker results — and provides the accurate answer they need to manage their flocks and egg production."

Neogen, in cooperation with USDA scientists, began the development of this test in 2000.

"Using a rapid test for SE that uses the same sample enrichment protocol as the FDA not only allows analysts to quickly screen out negative test results, but also is compatible with the FDA confirmation process by using the same enriched samples," said Bradley. "Especially now, with the heightened concern for contaminated eggs, time is of the essence."

The foodborne illness caused by SE is generally due to eating raw, incompletely cooked, or recontaminated eggs. Ingestion of SE-contaminated poultry meat is the second leading cause of this illness.

Neogen's comprehensive line of products it offers to the poultry industry also includes a full line of agricultural cleaners and disinfectants, and rodenticides, to stop the spread of infectious disease from animal to animal, and from production facilities to the consumer.

Neogen Corporation develops and markets products dedicated to food and animal safety. The company's Food Safety Division markets diagnostic test kits to detect foodborne bacteria, natural toxins, genetic modifications, food allergens, drug residues, plant diseases, and sanitation concerns, and dehydrated culture media. Neogen's Animal Safety Division markets a complete line of diagnostics, veterinary instruments, veterinary pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.


'/>"/>
SOURCE Neogen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System
2. Neogens Rapid Test for Salmonella enteritidis Receives AOAC Approval
3. Reportlinker Adds Global Automated And Rapid Microbiological Tests Industry
4. Precision Therapeutics Growing Rapidly as it Augments Research and Development Efforts
5. Rapid Increase in the Number of Worldwide Nanotechnology Degree Programs
6. Celsis Rapid Detections Updated Drug Master Files (DMFs) Accepted by FDA
7. An optical traffic cop for rapid communication
8. Maine Medical Center Chooses Business Intelligence Solution from Rapid Insight Inc.
9. RESolutions Rapid Enrollment Solutions, LLC Announces Launch of Novel Patient Recruitment Web Site - Clinical Trial Spotlight™
10. Wound Management Technologies, Inc. Rapidly Expands Its International Presence
11. Study: Era of Rapid Growth in Biomedical Research Over
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):